Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
The treatment landscape of classical Hodgkin lymphoma (cHL) has undergone significant
changes over the past 20 years. Gradual improvements have been made in the …
changes over the past 20 years. Gradual improvements have been made in the …
[HTML][HTML] Antibody based therapies in Hodgkin lymphoma
VS Radhakrishnan, J Longley, PWM Johnson - Cancer Treatment Reviews, 2024 - Elsevier
Multimodality treatment approaches, with systemic therapies at their core, have made
Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy …
Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy …
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study
NS Grover, G Hucks, ML Riches, A Ivanova… - The Lancet …, 2024 - thelancet.com
Background Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
promising activity when preceded by lymphodepleting chemotherapy. We aimed to …
Safety and Efficacy of CD30. CAR-T Cells as Consolidation Post Autologous Transplant in High-Risk CD30 Lymphoma
N Grover, G Hucks, M Riches, A Ivanova, D Moore… - papers.ssrn.com
Background: Chimeric antigen receptor T cells targeting CD30 (CD30. CAR) are safe and
with promising efficacy when preceded by lymphodepleting chemotherapy. Methods: In a …
with promising efficacy when preceded by lymphodepleting chemotherapy. Methods: In a …